SANOFI PASTEUR

🇫🇷France

Country: 🇫🇷France

Ownership: Subsidiary

Established: 1990-01-01

Employees: 10K

Market Cap: -

Website: http://www.sanofipasteur.com

Clinical Trials

Effectiveness of Adacel Vaccination in Pregnancy at Preventing Pertussis in Infants < 2 Months of Age in the United States

Completed

Conditions: Pertussis (Whooping Cough)

Interventions: Other: Not applicable / dataset analysis

First Posted Date: 2021-09-10

Last Posted Date: 2023-04-13

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 462

Registration Number: NCT05040802

Locations: 🇫🇷
Sanofi Pasteur, Lyon, France

Study on an Investigational Yellow Fever Vaccine Compared With Stamaril in Adults in Europe and Asia

Phase 2

Active, not recruiting

Conditions: Yellow Fever

Interventions: Biological: Yellow fever vaccine
Biological: Yellow fever vaccine (produced on serum-free Vero cells)

First Posted Date: 2021-08-18

Last Posted Date: 2025-05-21

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 690

Registration Number: NCT05011123

Locations: 🇫🇮
Investigational Site Number : 2460003, Turku, Finland
🇹🇭
Investigational Site Number : 7640002, Bangkok, Thailand
🇸🇬
Investigational Site Number : 7020001, Singapore, Singapore

and more 20 locations

Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine

Phase 2

Completed

Conditions: Influenza Immunization
Healthy Volunteers

Interventions: Biological: Quadrivalent Inactivated Influenza High Dose
Biological: COVID-19 mRNA Vaccine (nucleoside modified)

First Posted Date: 2021-07-20

Last Posted Date: 2023-10-03

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 306

Registration Number: NCT04969276

Locations: 🇺🇸
Investigational Site Number :8400003, Glendale, Arizona, United States
🇺🇸
Investigational Site Number :8400001, Peoria, Illinois, United States
🇺🇸
Investigational Site Number :8400006, San Diego, California, United States

and more 3 locations

Study on an Investigational Yellow Fever Vaccine Compared With YF-VAX in Adults in the USA

Phase 2

Active, not recruiting

Conditions: Yellow Fever (Healthy Volunteers)

Interventions: Biological: Yellow fever vaccine (produced on serum-free Vero cells)
Biological: Yellow fever vaccine

First Posted Date: 2021-06-28

Last Posted Date: 2023-06-22

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 567

Registration Number: NCT04942210

Locations: 🇺🇸
SUNY Upstate Medical University-Site Number:8400006, Syracuse, New York, United States
🇺🇸
MedPharmics-Site Number:8400008, Metairie, Louisiana, United States
🇺🇸
Emory University Decatur-Site Number:8400005, Decatur, Georgia, United States

and more 8 locations

Study on an Investigational Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Administered as a 5- and/or 10-year Booster Doses in Children and Adolescents Vaccinated 5 or 10 Years Earlier as Toddlers

Phase 3

Active, not recruiting

Conditions: Meningococcal Immunisation
Healthy Volunteers

Interventions: Biological: Meningococcal Polysaccharide (Serogroups A, C, W, and Y) Tetanus Toxoid Conjugate Vaccine

First Posted Date: 2021-06-23

Last Posted Date: 2024-05-08

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 209

Registration Number: NCT04936685

Locations: 🇩🇪
Investigational Site Number : 2760002, Mönchengladbach, Germany
🇫🇮
Investigational Site Number : 2460002, Järvenpää, Finland
🇫🇮
Investigational Site Number : 2460010, Turku, Finland

and more 23 locations

Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older

Phase 3

Completed

Conditions: COVID-19

Interventions: Biological: Placebo
Biological: SARS-CoV-2 adjuvanted recombinant protein vaccine (bivalent D614 + B.1.351) (primary series)
Biological: SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent D614) (primary series)
Biological: SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent B.1.351) (booster dose) >= 4 months after last vaccination
Biological: SARS-CoV-2 adjuvanted recombinant protein vaccine(monovalent D614)(primary series)& SARS-CoV-2 adjuvanted recombinant protein vaccine(monovalent B.1.351)(booster dose)>=4 months after last vaccination

First Posted Date: 2021-05-27

Last Posted Date: 2024-10-16

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 23726

Registration Number: NCT04904549

Locations: 🇺🇸
AES - DRS - Simon Williamson Clinic, PC - Birmingham Site Number : 8400004, Birmingham, Alabama, United States
🇺🇸
Optimal Research Alabama Site Number : 8400019, Huntsville, Alabama, United States
🇺🇸
Peninsula Research Associates, Inc. Site Number : 8400021, Rolling Hills Estates, California, United States

and more 83 locations

Observational, Passive Surveillance Program to Collect Information on Women and Their Offspring Exposed to MenQuadfi® During Pregnancy, in United States (US)

Recruiting

Conditions: Meningococcal Infection

Interventions: Biological: Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine

First Posted Date: 2021-04-13

Last Posted Date: 2024-11-04

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 50

Registration Number: NCT04843111

Locations: 🇺🇸
Pennsylvania Locations, Swiftwater, Pennsylvania, United States

Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants

Phase 1

Terminated

Conditions: Healthy Volunteers
Meningococcal Immunisation

Interventions: Drug: Meningococcal Group B Vaccine MenB
Drug: Multicomponent Meningococcal B Vaccine
Drug: Placebo
Drug: Meningococcal Group B Vaccine (recombinant deoxyribonucleic acid [rDNA], component, adsorbed)
Drug: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine MenACYW conjugate vaccine

First Posted Date: 2021-04-01

Last Posted Date: 2024-08-27

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 576

Registration Number: NCT04825223

Locations: 🇺🇸
California Research Foundation Site Number : 8400005, San Diego, California, United States
🇺🇸
Lakeview Clinical Research Site Number : 8400029, Guntersville, Alabama, United States
🇺🇸
Hope Clinical Research, Inc. Site Number : 8400001, Canoga Park, California, United States

and more 19 locations

Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older

Phase 1

Terminated

Conditions: COVID-19

Interventions: Biological: SARS-CoV-2 mRNA vaccine formulation 2
Biological: SARS-CoV-2 mRNA vaccine formulation 1
Biological: Placebo (0.9% normal saline)
Biological: SARS-CoV-2 mRNA vaccine formulation 3

First Posted Date: 2021-03-15

Last Posted Date: 2023-12-15

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 182

Registration Number: NCT04798027

Locations: 🇺🇸
Investigational Site Number :8400003, Rolling Hills Estates, California, United States
🇺🇸
Investigational Site Number :8400002, Hollywood, Florida, United States
🇺🇸
Investigational Site Number :8400017, Iowa City, Iowa, United States

and more 18 locations

Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older

Phase 2

Completed

Conditions: COVID-19

Interventions: Biological: SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 3
Biological: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03
Biological: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 4
Biological: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage B
Biological: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 2
Biological: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage A
Biological: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 3
Biological: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 1
Biological: SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 1
Biological: SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 2
Biological: SARS-CoV-2 adjuvanted recombinant protein vaccine, bivalent (D614+B.1.351)-AS03

First Posted Date: 2021-02-21

Last Posted Date: 2025-02-20

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 3385

Registration Number: NCT04762680

Locations: 🇫🇷
Investigational Site Number : 2500007, Pierre Benite, France
🇫🇷
Investigational Site Number : 2500004, Rennes, France
🇫🇷
Investigational Site Number : 2500002, Tours Cedex 1, France

and more 63 locations

Home Terms & Conditions Privacy Policy